Your browser doesn't support javascript.

Portal Regional da BVS

Informação e Conhecimento para a Saúde

Home > Pesquisa > ()
Imprimir Exportar

Formato de exportação:


Adicionar mais destinatários
| |

The Loading of Luminescent Magnetic Nanocomposites Fe3O4@Polyaniline/Carbon Dots for Methotrexate and Its Release Behavior In Vitro.

J Nanosci Nanotechnol; 20(2): 701-708, 2020 Feb 01.
Artigo em Inglês | MEDLINE | ID: mdl-31383065
In the present study we developed novel luminescent magnetic nanocomposites termed Fe3O4@polyaniline/carbon dots. First, Fe3O4 magnetic nanoparticles were prepared by the coprecipitation method. The nanoparticles were then coated with polyaniline using the in situ growth method to form Fe3O4@polyaniline nanohybrids, which were endowed with amino functional groups on the surface and avoided the aggregation of Fe3O4 nanoparticles. The X-ray diffraction pattern demonstrated that the crystalline phase of the Fe3O4 nanoparticles was an inverse spinel structure and was not changed in the Fe3O4@polyaniline nanohybrids. The saturation magnetization and the coercive force of the as-prepared Fe3O4@polyaniline nanohybrids measured by a vibrating sample magnetizer were 63.7 emu·g-1 and zero respectively, which indicated that the Fe3O4@polyaniline nanohybrids exhibited excellent superparamagnetism. The Fe3O4@polyaniline nanohybrids were conjugated with carbon dots, prepared from orange juice, via the amide bond between the amino groups on the surface of the Fe3O4@polyaniline nanohybrids and the carboxyl groups on the surface of carbon dots. The obtained luminescent magnetic nanocomposites Fe3O4@polyaniline/carbon dots showed good photoluminescent properties, which hinted that the nanocomposites have potential in drug tracing and magnetic targeted drug delivery. Finally, the anticancer drug methotrexate was loaded into the Fe3O4@polyaniline/carbon dots nanocomposites, forming a novel magnetic targeted drug delivery system. The results confirmed that the novel drug delivery system exhibited excellent drug-loading capability for methotrexate of ca. 70%, and emits strong fluorescence at the wavelength of 360 nm. An in vitro release experiment of the drug delivery system indicated that the cumulative release percentage of methotrexate was 17.2% in the phosphate-buffered saline (pH = 7.4) within 36 h.